

ABSTRACT OF THE DISCLOSURE

Chimeric antibodies specific to human CD4 antigen, DNA encoding, pharmaceutical compositions containing and use  
5 thereof as therapeutic agents are taught. These chimeric antibodies contain Old World monkey variable sequences and human constant domain sequences, preferably human gamma 1, gamma 4 or mutated forms thereof. These antibodies possess desirable therapeutic properties including low antigenicity,  
10 reduced (or absent) T cell depleting activity, good affinity to human CD4 and enhanced stability (in vivo half-life).

DO NOT DESTROY  
2025 RELEASE UNDER E.O. 14176